Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
While glyco-engineered monoclonal antibodies (mAbs) with improved antibody-dependent cell-mediated cytotoxicity (ADCC) are reaching the market, extensive efforts have also been made to improve their pharmacokinetic properties to generate biologically superior molecules. Most therapeutic mAbs are human or humanized IgG molecules whose half-life is dependent on the neonatal Fc receptor FcRn. FcRn reduces IgG catabolism by binding to the Fc domain of endocytosed IgG in acidic lysosomal compartments, allowing them to be recycled into the blood. Fc-engineered mAbs with increased FcRn affinity resulted in longer in vivo half-life in animal models, but also in healthy humans. These Fc-engineered mAbs were obtained by alanine scanning, directed mutagenesis or in silico approach of the FcRn binding site. In our approach, we applied a random mutagenesis technology (MutaGen™) to generate mutations evenly distributed over the whole Fc sequence of human IgG1. IgG variants with improved FcRn-binding were then isolated from these Fc-libraries using a pH-dependent phage display selection process. Two successive rounds of mutagenesis and selection were performed to identify several mutations that dramatically improve FcRn binding. Notably, many of these mutations were unpredictable by rational design as they were located distantly from the FcRn binding site, validating our random molecular approach. When produced on the EMABling(®) platform allowing effector function increase, our IgG variants retained both higher ADCC and higher FcRn binding. Moreover, these IgG variants exhibited longer half-life in human FcRn transgenic mice. These results clearly demonstrate that glyco-engineering to improve cytotoxicity and protein-engineering to increase half-life can be combined to further optimize therapeutic mAbs.
LFB Biotechnologies; Lille, France.
Céline
C
Monnet
LFB Biotechnologies; Lille, France.
Sylvie
S
Jorieux
MilleGen; Labège, France.
Nathalie
N
Souyris
MilleGen; Labège, France.
Ouafa
O
Zaki
LFB Biotechnologies; Lille, France.
Alexandra
A
Jacquet
LFB Biotechnologies; Lille, France.
Nathalie
N
Fournier
MilleGen; Labège, France.
Fabien
F
Crozet
LFB Biotechnologies; Lille, France.
Christophe
C
de Romeuf
MilleGen; Labège, France.
Khalil
K
Bouayadi
LFB Biotechnologies; Courtaboeuf, France.
Rémi
R
Urbain
LFB Biotechnologies; Courtaboeuf, France.
Christian K
CK
Behrens
LFB Biotechnologies; Lille, France.
Philippe
P
Mondon
LFB Biotechnologies; Lille, France.
Alexandre
A
Fontayne
D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000493:pharmacokinetics*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000235:genetics; D061505:Cell Surface Display Techniques; D003602:Cytotoxicity, Immunologic / Q000235:genetics; D006031:Glycosylation; D006207:Half-Life; D015395:Histocompatibility Antigens Class I / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007074:Immunoglobulin G / Q000235:genetics / Q000378:metabolism*; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D051379:Mice; D008822:Mice, Transgenic; D016297:Mutagenesis, Site-Directed; D009154:Mutation / Q000235:genetics; D015202:Protein Engineering / Q000379:methods*; D011961:Receptors, Fc / Q000235:genetics / Q000378:metabolism*; D017452:Receptors, IgG / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism
D000911:Antibodies, Monoclonal; C496124:FCGR3A protein, human; C080568:Fc gamma receptor IIA; D015395:Histocompatibility Antigens Class I; D007074:Immunoglobulin G; D011961:Receptors, Fc; D017452:Receptors, IgG; C100688:Fc receptor, neonatal
ADCC; Fc-engineering; FcRn; glycoengineering; phage display; pharmacokinetics; random mutagenesis